Laura van’t Veer, Inventor of Agendia’s MammaPrint Breast Cancer Assay, Honored with Luminary Award at Precision Medicine World Conference (PMWC 2020)

Laura van ‘t Veer (photo here, also see more photos at end), PhD, Co-Founder of Agendia Inc. and developer of MammaPrint, the 70-gene risk of recurrence assay for breast cancer patients, was recognized by the Precision Medicine World Conference (PMWC) with the PMWC Luminary Award on January 21, 2020. This award recognizes individuals who have made significant contributions to accelerate personalized medicine within the clinical setting. As a Professor of Laboratory Medicine and Director of Applied Genomics at the University California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, Dr. van ‘t Veer is committed to translational medicine that aims to leverage the genomic makeup of patient tumors and improve their clinical outcomes. Dr. van ‘t Veer has authored more than 280 peer-reviewed scientific articles and is a co-inventor on 6 patents. In 2007, she received the European Society of Medical Oncology (ESMO) life-time achievement award for translational research in breast cancer, in 2014 the European Union Women Innovator Award, and in 2015 the EPO European Inventor award. In 2019, she was recognized by 24/7 Wall Street as one of “32 Amazing Women Inventors.” Currently, Dr. van ‘t Veer serves as the Biomarker Committee Chair for the Quantum Leap Healthcare Collaborative (QLHC)-sponsored I-SPY 2 adaptive clinical trial. By using genomic information obtained from participating patients, this trial seeks to elucidate how different tumors will respond to novel drug regimens, thus improving patient outcomes. At the PMWC Awards Reception, Dr. van’t Veer was introduced by Agendia CEO Mark Straley. Tal Bahar Co-Founder and President, PMWC commented:
Login Or Register To Read Full Story